Q4 2017 EPS Estimates for Halyard Health, Inc. Cut by KeyCorp (HYH)
Halyard Health, Inc. (NYSE:HYH) – Investment analysts at KeyCorp reduced their Q4 2017 earnings estimates for Halyard Health in a research report issued to clients and investors on Wednesday. KeyCorp analyst M. Mishan now forecasts that the medical instruments supplier will earn $0.49 per share for the quarter, down from their previous forecast of $0.51.
Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.14. The business had revenue of $399.20 million for the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.45 EPS.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/q4-2017-eps-estimates-for-halyard-health-inc-cut-by-keycorp-hyh.html.
Other analysts also recently issued reports about the company. TheStreet upgraded Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. Deutsche Bank AG lifted their target price on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday. Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research report on Wednesday, July 12th. BidaskClub upgraded Halyard Health from a “hold” rating to a “buy” rating in a research report on Wednesday, June 28th. Finally, Stephens upgraded Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Halyard Health currently has a consensus rating of “Buy” and an average target price of $42.25.
Several institutional investors have recently made changes to their positions in the stock. CENTRAL TRUST Co raised its position in shares of Halyard Health by 1.0% in the first quarter. CENTRAL TRUST Co now owns 2,643 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 25 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in shares of Halyard Health by 1.1% in the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 28 shares in the last quarter. Glen Harbor Capital Management LLC raised its position in shares of Halyard Health by 1.1% in the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 34 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Halyard Health during the first quarter valued at approximately $153,000. Finally, LS Investment Advisors LLC raised its position in shares of Halyard Health by 16.1% in the second quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 556 shares in the last quarter. Hedge funds and other institutional investors own 90.28% of the company’s stock.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.